Core Insights - Allogene Therapeutics is at a critical juncture with the upcoming interim data from the ALPHA3 trial of cema-cel, which aims to determine if early, MRD-guided allogeneic CAR T therapy can prevent relapse in large B-cell lymphoma (LBCL) [2][3] - The company is focused on demonstrating that allogeneic CAR T can be delivered at a biologic-like scale, moving beyond academic settings [2][4] - Allogene has a cash runway extending into Q1 2028, allowing for disciplined execution and data delivery across its portfolio [2][13] Company Updates - The ALPHA3 trial is designed to evaluate cema-cel as a "7th cycle" of first-line therapy, integrating it without altering existing treatment workflows [4] - The trial is enrolling patients at over 60 clinical sites, including both academic and community cancer centers, to enhance patient access [4] - An interim futility analysis is scheduled for April 2026, which will compare MRD clearance rates between cema-cel and observation [5] Product Development - ALLO-329 is a next-generation allogeneic CAR T therapy targeting CD19/CD70, utilizing proprietary Dagger technology for built-in lymphodepletion [6][10] - The Phase 1 RESOLUTION trial for ALLO-329 is currently enrolling patients across multiple autoimmune indications, with proof-of-concept data expected in June 2026 [7][10] - ALLO-316 has shown significant response rates in metastatic solid tumors, with the TRAVERSE trial completed and the company exploring partnership opportunities [11] Financial Performance - As of December 31, 2025, Allogene reported $258.3 million in cash, cash equivalents, and investments, extending its cash runway into Q1 2028 [12][13] - Research and development expenses for Q4 2025 were $28.6 million, totaling $150.2 million for the full year [16] - The net loss for Q4 2025 was $38.8 million, or $0.17 per share, with a full-year net loss of $190.9 million, or $0.87 per share [16][22]